NSE: AARTIDRUGS | BSE: 524348

Strong Performer, Getting Expensive

Download real time

515.20 6.80 (1.34%)

65.13% Gain from 52W Low

149.8K NSE+BSE Volume

NSE 10 Oct, 2025 3:31 PM (IST)

4,702.2

Market Cap

Above industry Median

0.9

Beta 1Year

Low volatility

Aarti Drugs Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for AARTIDRUGS, BSE:524348 Aarti Drugs Ltd.

Aarti Drugs Ltd.

27 Oct 2020

515.20

1.34%

Result Update:Aarti Drugs

Buy: Aarti Drugs Ltd.

Axis Direct

We expect revenue and PAT CAGR of 18.2% and 37.6% respectively over the period FY20-FY23E and recommend "Buy" with TP of INR 812.

Aarti Drugs Ltd. is trading above all available SMAs

Aarti Drugs Ltd.

04 Oct 2018

515.20

1.34%

Aarti Drugs

Buy: Aarti Drugs Ltd.

Target

Centrum Broking

We maintain our Buy rating on Aarti Drugs (ADL) and retain the TP to Rs910 based on 16x March'20 EPS of Rs56.8. ADL is the market leader in 9 out of 10 APIs manufactured by the company. That said, the company is likely to benefit from vertical integration which is likely to drive future growth. We expect margins to improve post the launch of new products and additional capacities of Ciprofloxacin and Metformin APIs in place. Key risks to our assumptions include...

Number of FII/FPI investors decreased from 96 to 73 in Jun 2025 qtr

Aarti Drugs Ltd.

17 May 2018

515.20

1.34%

Aarti Drugs

Buy: Aarti Drugs Ltd.

Target

Centrum Broking

We maintain our Buy rating on Aarti Drugs (ADL) and revise the TP to Rs960 (earlier TP Rs940) based on 16x March'20 EPS of Rs60.1. AIL's Q4FY18 results exceeded our expectations. The pharma major's revenue grew 3% YoY, margin improved 260bps to 17.1% and net profit grew 10% YoY. That said, the company is likely to benefit from vertical integration which is likely to drive future growth. We expect margins to improve post the launch of new products and additional capacities of Ciprofloxacin and Metformin APIs coming on stream. Key risks to our assumptions include slowdown in the domestic pharma market and regulatory...

Number of FII/FPI investors decreased from 96 to 73 in Jun 2025 qtr

Aarti Drugs Ltd.

15 Jan 2018

515.20

1.34%

Aarti Drugs

Buy: Aarti Drugs Ltd.

Centrum Broking

Valuation and key risks: We see strong scope for re-rating and ADL using our conservative five-year AOCF/EV yield method to arrive at a TP of Rs940, implying an upside of 25% over CMP. We expect the company to report RoE of 23% and RoCE of 15% for FY20. ADL outscores many of its peers due to its efficacious presence in the domestic and emerging markets and its integration across the value chain. Key risks to our call include slowdown in the domestic market and regulatory risks for its...

Number of FII/FPI investors decreased from 96 to 73 in Jun 2025 qtr

Aarti Drugs Ltd.

17 Aug 2016

515.20

1.34%

In-line; Topline disappoints; Lower oil prices impact pricing; LATAM

Hold: Aarti Drugs Ltd.

Motilal Oswal

1QFY17 results were in-line with our estimates with Revenues, EBITDA and PAT growing at 3%, 9% and 15% respectively. Inspite of the expanded capacities in anti-protozoals in 4QFY16 sales grew by a palty 3% to INR 292cr as lower crude prices impacted sales / product pricing in Africa and Middle East. Certain LATAM countries witnessed...

Aarti Drugs Ltd. has an average target of 475.00 from 1 broker.

Is Aarti Drugs Ltd. worth buying?

747 Votes:

Buy 77.91%

Sell 11.38%

Hold 10.71%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf